Contract award · HDTRA124C0008
GENERATION OF A NOVEL ANTIBODY-ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIOIDOSIS OR PLAGUE.
Awarded to MINISTRY OF DEFENCE · CAGE KB887
Latest reported total obligated
Not reported
Net observed obligations
$5.6M
Observed contract actions
10
Observed period
FY2024–FY2026
Reported totals are cumulative values from the latest available award record. Observed obligations and actions reflect Mimir's FY2019 onward transaction window and may omit earlier activity.
Award parties and scope
ContractorMINISTRY OF DEFENCE
CAGEKB887
CustomerDefense Threat Reduction Agency
Performance locationSALISBURY, UNITED KINGDOM
Procurement details
First observed actionJun 6, 2024
Latest observed actionMay 18, 2026
PSCAC32
NAICS541714 · Research and Development in Biotechnology (except Nanobiotechnology)
CompetitionFULL AND OPEN COMPETITION
PricingCOST PLUS FIXED FEE
SolicitationHDTRA114S0001
Annual observed obligations
FY2024
$534.6K
FY2025
$1.6M
FY2026
$3.5M
Continue exploring
Ask Mimir about HDTRA124C0008
Continue with this contract award already in context.
ContinueExplore the full award in Mimir
Open the complete action history and connected analysis in the platform.